HRP20170517T1 - Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikoheksan-1,1'-pirano[3,4,b]indol]-4-amin i antikonvulziv - Google Patents
Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikoheksan-1,1'-pirano[3,4,b]indol]-4-amin i antikonvulziv Download PDFInfo
- Publication number
- HRP20170517T1 HRP20170517T1 HRP20170517TT HRP20170517T HRP20170517T1 HR P20170517 T1 HRP20170517 T1 HR P20170517T1 HR P20170517T T HRP20170517T T HR P20170517TT HR P20170517 T HRP20170517 T HR P20170517T HR P20170517 T1 HRP20170517 T1 HR P20170517T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmacologically active
- active ingredient
- pain
- dosage form
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12003898 | 2012-05-18 | ||
| EP13159330 | 2013-03-15 | ||
| EP13723004.1A EP2852384B1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an anticonvulsant |
| PCT/EP2013/001471 WO2013170972A1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an anticonvulsant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170517T1 true HRP20170517T1 (hr) | 2017-06-02 |
Family
ID=48446244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170517TT HRP20170517T1 (hr) | 2012-05-18 | 2013-05-16 | Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikoheksan-1,1'-pirano[3,4,b]indol]-4-amin i antikonvulziv |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9345689B2 (enExample) |
| EP (1) | EP2852384B1 (enExample) |
| JP (1) | JP6116679B2 (enExample) |
| CN (1) | CN104284656A (enExample) |
| AU (1) | AU2013262078B2 (enExample) |
| CA (1) | CA2873871A1 (enExample) |
| CY (1) | CY1118634T1 (enExample) |
| DK (1) | DK2852384T3 (enExample) |
| EA (1) | EA029767B1 (enExample) |
| ES (1) | ES2624220T3 (enExample) |
| HR (1) | HRP20170517T1 (enExample) |
| HU (1) | HUE031984T2 (enExample) |
| IL (1) | IL235654A (enExample) |
| LT (1) | LT2852384T (enExample) |
| MX (1) | MX353177B (enExample) |
| PL (1) | PL2852384T3 (enExample) |
| PT (1) | PT2852384T (enExample) |
| RS (1) | RS55905B1 (enExample) |
| SI (1) | SI2852384T1 (enExample) |
| WO (1) | WO2013170972A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2974578C (en) | 2015-01-23 | 2020-11-17 | Grunenthal Gmbh | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
| US20190060284A1 (en) * | 2016-02-26 | 2019-02-28 | The Johns Hopkins University | Pharmacological modulators of nav1.1 voltage-gated sodium channels associated with mechanical pain |
| US20190125725A1 (en) * | 2016-05-12 | 2019-05-02 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
| JP7264813B2 (ja) * | 2016-12-06 | 2023-04-25 | トピカル・イノベーションズ・ベー・フェー | 末梢神経障害性疼痛の治療に使用するための局所作用用フェニトイン |
| EP3826610A4 (en) * | 2018-07-24 | 2022-05-04 | Zenvision Pharma LLP | Nasal drug delivery system of brivaracetam or salt thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US5708035A (en) | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
| US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| US20030056896A1 (en) * | 1995-05-12 | 2003-03-27 | Frank Jao | Effective therapy for epilepsies |
| US6117900A (en) | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
| US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DK1567164T3 (da) | 2002-11-26 | 2009-05-18 | Alexza Pharmaceuticals Inc | Anvendelse af loxapin til fremstilling af et lægemiddel til behandling af smerte |
| US20040222123A1 (en) * | 2003-05-06 | 2004-11-11 | Barr Laboratories, Inc. | Kit for pharmaceuticals |
| CN1245379C (zh) | 2003-10-30 | 2006-03-15 | 曹桂东 | 加巴喷丁的制法 |
| DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| GB0412878D0 (en) | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Use |
| US20080261984A1 (en) | 2004-06-09 | 2008-10-23 | Pfizer Inc. | Use of S,S-Reboxetine in the Treatment of Pain |
| US8093408B2 (en) | 2005-06-21 | 2012-01-10 | The Company Wockhardt | Antidepressant oral pharmaceutical compositions |
| US20080014264A1 (en) | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
| DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| JP2008106028A (ja) * | 2006-10-26 | 2008-05-08 | Boehringer Ingelheim Internatl Gmbh | 慢性疼痛の治療におけるフリバンセリンの使用 |
| US20080153874A1 (en) | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
| WO2008108639A1 (en) | 2007-03-08 | 2008-09-12 | Avantium Holding B.V. | Co-crystalline forms of carbamazepine |
| EP1977744A1 (en) | 2007-04-03 | 2008-10-08 | Chemo Ibérica, S.A. | Polymorphic Form alpha of (S)-Pregabalin and process for its preparation |
| ES2373838T3 (es) * | 2007-12-21 | 2012-02-09 | Horizon Pharma Ag | Medicamento así como su preparación y su utilización en el tratamiento de neuropatías dolorosas. |
| US20090298947A1 (en) | 2008-05-28 | 2009-12-03 | Pliva Hrvatska D.O.O. | Polymorphic and amorphous forms of lacosamide and amorphous compositions |
| JP5731387B2 (ja) * | 2008-09-05 | 2015-06-10 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 医薬配合剤 |
| DE102009013613A1 (de) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Trockenverarbeitung von Retigabin |
| DK2600851T3 (en) * | 2010-08-04 | 2018-06-25 | Gruenenthal Gmbh | PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NEUROPATHIC PAIN |
| EP2600846B1 (en) * | 2010-08-04 | 2015-11-25 | Grünenthal GmbH | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| PE20131108A1 (es) * | 2010-08-04 | 2013-10-17 | Gruenenthal Chemie | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina |
-
2013
- 2013-05-13 US US13/892,751 patent/US9345689B2/en not_active Expired - Fee Related
- 2013-05-16 RS RS20170381A patent/RS55905B1/sr unknown
- 2013-05-16 HU HUE13723004A patent/HUE031984T2/en unknown
- 2013-05-16 EP EP13723004.1A patent/EP2852384B1/en not_active Not-in-force
- 2013-05-16 CN CN201380025637.XA patent/CN104284656A/zh active Pending
- 2013-05-16 EA EA201401271A patent/EA029767B1/ru not_active IP Right Cessation
- 2013-05-16 PT PT137230041T patent/PT2852384T/pt unknown
- 2013-05-16 MX MX2014013179A patent/MX353177B/es active IP Right Grant
- 2013-05-16 PL PL13723004T patent/PL2852384T3/pl unknown
- 2013-05-16 AU AU2013262078A patent/AU2013262078B2/en not_active Ceased
- 2013-05-16 HR HRP20170517TT patent/HRP20170517T1/hr unknown
- 2013-05-16 CA CA2873871A patent/CA2873871A1/en not_active Abandoned
- 2013-05-16 JP JP2015511958A patent/JP6116679B2/ja active Active
- 2013-05-16 SI SI201330569A patent/SI2852384T1/sl unknown
- 2013-05-16 LT LTEP13723004.1T patent/LT2852384T/lt unknown
- 2013-05-16 ES ES13723004.1T patent/ES2624220T3/es active Active
- 2013-05-16 DK DK13723004.1T patent/DK2852384T3/en active
- 2013-05-16 WO PCT/EP2013/001471 patent/WO2013170972A1/en not_active Ceased
-
2014
- 2014-11-12 IL IL235654A patent/IL235654A/en active IP Right Grant
-
2017
- 2017-02-15 CY CY20171100205T patent/CY1118634T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2852384T1 (sl) | 2017-04-26 |
| WO2013170972A1 (en) | 2013-11-21 |
| US9345689B2 (en) | 2016-05-24 |
| CY1118634T1 (el) | 2017-07-12 |
| EP2852384A1 (en) | 2015-04-01 |
| HUE031984T2 (en) | 2017-08-28 |
| MX2014013179A (es) | 2015-01-19 |
| IL235654A (en) | 2017-07-31 |
| CA2873871A1 (en) | 2013-11-21 |
| IL235654A0 (en) | 2015-01-29 |
| LT2852384T (lt) | 2017-04-25 |
| AU2013262078B2 (en) | 2017-10-26 |
| DK2852384T3 (en) | 2017-05-08 |
| PT2852384T (pt) | 2017-05-10 |
| PL2852384T3 (pl) | 2017-09-29 |
| US20130317009A1 (en) | 2013-11-28 |
| RS55905B1 (sr) | 2017-09-29 |
| JP2015516452A (ja) | 2015-06-11 |
| JP6116679B2 (ja) | 2017-04-19 |
| EA201401271A1 (ru) | 2015-05-29 |
| EA029767B1 (ru) | 2018-05-31 |
| AU2013262078A1 (en) | 2015-01-22 |
| CN104284656A (zh) | 2015-01-14 |
| ES2624220T3 (es) | 2017-07-13 |
| HK1204937A1 (en) | 2015-12-11 |
| MX353177B (es) | 2018-01-05 |
| EP2852384B1 (en) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290394A1 (ru) | Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7 | |
| HRP20170517T1 (hr) | Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikoheksan-1,1'-pirano[3,4,b]indol]-4-amin i antikonvulziv | |
| EA200870448A1 (ru) | Тризамещенные 1,2,4-триазолы | |
| WO2013003629A3 (en) | Methods and compositions for inhibition of bone resorption | |
| MX2009010759A (es) | Derivados de carboxamida imidazolidina como modulares de p2x7. | |
| EA201071094A1 (ru) | Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| RU2018108202A (ru) | Способы лечения синдрома леннокса-гасто с использованием фенфлурамина | |
| EA200970706A1 (ru) | Новые фармацевтические композиции | |
| EA201071288A1 (ru) | Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина | |
| HRP20212030T1 (hr) | Kombinacija koja sadrži palbociklib i 6-(2,4-diklorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-8,9-dihidro-7h-benzo[7]anulen-2-karboksilnu kiselinu i njezina upotreba u liječenju raka | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| FI3658140T3 (fi) | Aprositentaanin yhdistelmiä muiden vaikuttavien ainesosien kanssa resistentin verenpainetaudin hoitamiseksi | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| DE602008005582D1 (de) | Pyrazolderivate als p2x7-modulatoren | |
| EA201490016A1 (ru) | Комбинация панобиностата и руксолитинаба при лечении рака, такого как миелопролиферативное новообразование | |
| FI2854769T3 (fi) | Artriitin hoitomenetelmät | |
| HRP20150375T1 (hr) | Derivati piridazinona | |
| KR101475538B1 (ko) | Ｈｄａｃ 억제제와 항대사물질의 조합물 | |
| HRP20170848T1 (hr) | Kompozicije i metode za liječenje pluće hipertenzije | |
| NZ595127A (en) | Stable pharmaceutical composition for atherosclerosis | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| JP2013518914A5 (enExample) | ||
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| HRP20171693T1 (hr) | Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen | |
| CR20120432A (es) | Formulaciones farmacéuticas sólidas de ramipril y besilato de amlodipino y su preparación |